AstraZeneca PLC Share Price and Company Fundamentals
Last traded: Last Friday at 3:44 PM
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
|Industry / Sector||Drug Manufacturers—General / Healthcare|
|Full time employees||76100|
|Mailing address||1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom|
|Phone / Fax||44 20 3749 5000 /|
5Y Avg. yield
AstraZeneca PLC paid £2.80 dividend and the ex-dividend date was 12 Aug 2021.The dividend payout ratio is 99.04%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AZN dividend payout ratio is more than 90% making it difficult for the company to maintain the dividends and increase it year by year.
AZN's forward dividend amount is £2.02 and the forward dividend yield is 2.51%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
As of Sep 2021, following are the company executives and directors listed on AstraZeneca PLC.
|Mr. Pascal Soriot D.V.M., M.B.A.||CEO & Exec. Director||61||4.39M|
|Mr. Marc Dunoyer||Chief Exec. Officer of Alexion||68||2.45M|
|Dr. Aradhana Sarin M.D.||CFO & Exec. Director||45|
|Ms. Pam P. Cheng||EVP of Operations & Information Technology and Member of External Sustainability Advisory Board||49|
|Mr. Thomas Kudsk Larsen||Head of Investor Relations||46|
|Mr. Jeffrey Pott||EVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board|
|Ms. Katarina Ageborg||EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board|
|Dr. Menelas Pangalos Ph.D.||EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board|
|Dr. Ruud Dobber Ph.D.||Exec. Vice-Pres of BioPharmaceuticals Bus. Unit|
|Dr. Susan Mary Galbraith M.D., Ph.D.||Exec. VP of Oncology R&D||54|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of AstraZeneca PLC is 124.91B and its enterprise value is 120.06B. The enterprise value to revenue ratio of AZN is 4.07.
The AZN's stocks Beta value is 0.19 making it 81% less volatile compared to LSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
AstraZeneca PLC (LSE:AZN) Frequently Asked Questions
1. What is AstraZeneca PLC's Stock Symbol?
AstraZeneca PLC trades on LSE under the ticker symbol "AZN".
2. What is AstraZeneca PLC's stock price today?
One share of AZN stock can currently be purchased for approximately £8063.
3. How can I contact AstraZeneca PLC?
AstraZeneca PLC's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom. The company can be reached via phone at 44 20 3749 5000.
4. What is AstraZeneca PLC's official website?
The official website of AstraZeneca PLC is http://www.astrazeneca.com.